Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pulmonx (LUNG)
NASDAQ:LUNG
Pulmonx (LUNG) Stock Price & Analysis
73 Followers
LUNG Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.21 - $14.84
Previous Close$7.5
Volume492.10K
Average Volume (3M)573.00K
Market Cap
$289.03M
Enterprise Value$213.35M
Total Cash (Recent Filing)$117.10M
Total Debt (Recent Filing)$41.42M
Price to Earnings (P/E)-4.7
Beta1.84
Next Earnings
May 01, 2024EPS Estimate
-$0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.60
Shares Outstanding38,537,356
10 Day Avg. Volume480,025
30 Day Avg. Volume573,005
Standard Deviation0.18
R-Squared0.03
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)2.49
Price to Sales (P/S)4.22
Price to Cash Flow (P/CF)-8.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.11
Enterprise Value/Gross Profit4.20
Enterprise Value/Ebitda-4.98
Forecast
1Y Price Target
$16.83Price Target Upside130.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Pulmonx News
Bulls Say, Bears Say
Bulls Say
Earnings GrowthLUNG has delivered strong growth with 2023 sales growing 28% year over year, signaling a robust upward trend in the company's financial performance.
Market ExpectationsLUNG's recent financial results showed a quarterly revenue of $19.3 million, exceeding market expectations and demonstrating the company's ability to surpass financial projections.
Operational ExpansionWith the addition of 14 new treating centers, LUNG is expanding its operational footprint, which is a strong indicator of the company's aggressive growth strategy and its potential to capture more market share.
Bears Say
Management StabilityRecent management changes, including the departure of the CFO and CEO, have created uncertainty about the company's future direction and strategy.
Market ExpansionSignificant opportunities in Japan are present, but material revenue is not expected until 2026.
Stock ValuationThe price target for the company has been lowered, reflecting a more cautious outlook on its valuation.
---
Ownership Overview
10.43% Insiders
39.13% Mutual Funds
17.90% Other Institutional Investors
32.55% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
ProductionRisks related to the company’s ability to manufacture goods and services
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LUNG FAQ
What was Pulmonx’s price range in the past 12 months?
Pulmonx lowest stock price was $7.21 and its highest was $14.84 in the past 12 months.
What is Pulmonx’s market cap?
Currently, no data Available
When is Pulmonx’s upcoming earnings report date?
Pulmonx’s upcoming earnings report date is May 01, 2024 which is in 5 days.
How were Pulmonx’s earnings last quarter?
Pulmonx released its earnings results on Feb 21, 2024. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.409 by $0.049.
Is Pulmonx overvalued?
According to Wall Street analysts Pulmonx’s price is currently Undervalued.
Does Pulmonx pay dividends?
Pulmonx does not currently pay dividends.
What is Pulmonx’s EPS estimate?
Pulmonx’s EPS estimate is -$0.47.
How many shares outstanding does Pulmonx have?
Pulmonx has 38,537,357 shares outstanding.
What happened to Pulmonx’s price movement after its last earnings report?
Pulmonx reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.409. Following the earnings report the stock price went down -18.207%.
Which hedge fund is a major shareholder of Pulmonx?
Among the largest hedge funds holding Pulmonx’s share is PRIMECAP Management Co. It holds Pulmonx’s shares valued at 72M.
---
Pulmonx Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.83 (130.55% Upside)
$16.83 (130.55% Upside)
Blogger Sentiment
Bullish
LUNG Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $128.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.30%
12-Months-Change
Fundamentals
Return on Equity
-44.68%
Trailing 12-Months
Asset Growth
-7.80%
Trailing 12-Months
Company Description
Pulmonx
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). the company's solutions comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the U.S. and international markets.
---
LUNG Earnings Call
Q4 2024
0:00 / 0:00
---
LUNG Stock 12 Months Forecast
Average Price Target
$16.83
▲(130.55% Upside)
Technical Analysis
Best Analysts Covering LUNG
1 Year
1 Year Success Rate
2/11 ratings generated profit
1 Year Average Return
-19.90%
reiterated a buy rating 2 months ago
Copying Joanne Wuensch's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -19.90% per trade.
---